Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Turn Therapeutics Inc ( (TTRX) ) has issued an update.
On November 11, 2025, Turn Therapeutics announced that its GX-03 technology was recognized by Patient Care Online Magazine as one of the ‘Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment.’ This recognition highlights the company’s innovative approach in dermatology, particularly with its topical IL36/IL31 inhibitor, which targets key inflammatory pathways in eczema and psoriasis. The announcement underscores Turn Therapeutics’ commitment to advancing its proprietary therapeutics pipeline, with plans to release topline data from its severe eczema program in early 2026.
More about Turn Therapeutics Inc
Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases. The company has received FDA clearances for its proprietary formulations and is advancing clinical programs in eczema and onychomycosis. Additionally, Turn is involved in global health initiatives aimed at thermostable vaccine delivery for underserved areas.
Average Trading Volume: 994,218
Find detailed analytics on TTRX stock on TipRanks’ Stock Analysis page.